Access Scientific’s PICC WAND receives FDA clearance Access Scientific offers received FDA clearance for The PICC WANDTM, which enables clinicians to put in a peelable sheath for Midline or PICC catheter positioning using the new Accelerated Seldinger Technique . The PICC WAND can be an all-in-one safety introducer that addresses the over-wire vascular access market, valued at a lot more than $1 billion, by giving faster, safer and simpler vascular access.D side effects ., CEO of Access Scientific. We firmly believe this marks the arrival of a new and higher regular of care. Air embolism is among the patient risks of MST that are reduced by The WAND and its Accelerated Seldinger Technique. In October 2008 Beginning, the Centers for Medicare & Medicaid Solutions ceased reimbursing healthcare institutions for atmosphere embolism, which CMS considers preventable.
Access initiated the Phase 4 medical trial of MuGard in 2010 2010 with 1st sites opened and subjects signed up for the first quarter of 2011. The designed trial is a prospective rigorously, randomized, multi-middle, double-blind, placebo-controlled research to evaluate the efficacy of MuGard in controlling symptoms due to oral mucositis in subjects receiving chemoradiation therapy for the treatment of cancers of the top and neck. The protocol, whose principal contributor was Stephen T. Sonis, DMD, DMSc, a thought head in oral mucositis, is made to evaluate MuGard with a rigor that’s typically associated with drugs or biological. Access believes this trial style is the first to be used to evaluate a gadget for an oral mucositis indication and distinguishes Gain access to and MuGard from competing companies and products.